Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease

Hai-Chen Lv\textsuperscript{1,*}, Hong-Yi Wu\textsuperscript{2,*}, Jia-Sheng Yin\textsuperscript{2} and Jun-Bo Ge\textsuperscript{2}

\textsuperscript{1}Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China
\textsuperscript{2}Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China
\textsuperscript{*}These authors have contributed equally to this work

Correspondence to: Jun-Bo Ge, email: ge.junbo2@zs-hospital.sh.cn

Keywords: coronary artery disease, thrombelastography, inflammatory marker, platelet volume index, platelet activation

Received: January 02, 2017  Accepted: April 11, 2017  Published: July 22, 2017

Copyright: Lv et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Platelet aggregation and inflammation are both implicated in coronary artery disease (CAD). Thrombin induced platelet-fibrin clot strength ($MA_{\text{Thrombin}}$) measured by thrombelastography (TEG) has been proved to be a novel marker of platelet aggregation. The aim of this study was to investigate the correlation of $MA_{\text{Thrombin}}$ to platelet volume indices (PVIs) or to inflammatory markers in different types of CAD. 206 patients with different types of CAD were enrolled. $MA_{\text{Thrombin}}$, PVIs, including mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR) as well as inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (Fbg) were measured. Multiple linear regression models were used to analyze the association between $MA_{\text{Thrombin}}$, PVIs, and inflammatory markers. $MA_{\text{Thrombin}}$ and inflammatory markers both varied with CAD types ($P<0.001$). $MA_{\text{Thrombin}}$ was correlated to PVIs in NSTEMI individuals (MPV, $r=0.393$, $P=0.007$; PDW, $r=0.334$, $P=0.023$; P-LCR, $r=0.382$, $P=0.008$), but had inner-link with inflammatory markers in STEMI cases (hs-CRP, $r=0.499$, $P<0.001$; Fbg, $r=0.500$, $P<0.001$). These findings may suggest different mechanisms of platelet aggregation in different types of CAD. Moreover, $MA_{\text{Thrombin}}$ may be used as a potential parameter to evaluate platelet aggregation and inflammation together.

INTRODUCTION

Platelet aggregation plays an important role in the pathogenesis of coronary artery disease (CAD) [1–4], but bedside monitoring of platelet aggregation is challenging clinically. Recently, thrombin induced platelet-fibrin clot strength ($MA_{\text{Thrombin}}$) measured by thrombelastography (TEG) has been suggested as a novel marker to identify platelet hyperaggregability in patients with acute myocardial infarction (AMI) [5]. In addition, previous studies have demonstrated that $MA_{\text{Thrombin}}$ could provide prognostic value on high platelet reactivity (HPR) after anti-platelet therapy [6–8]. However, the underlying determinants of $MA_{\text{Thrombin}}$ remain unclear.

Previous studies have indicated that platelet volume indices (PVIs), such as mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR), could elevate in patients with acute coronary syndrome (ACS), which might be due to larger platelets containing more pro-aggregating mediators and presenting more enhanced functions [9–11]. From this view, PVIs, perhaps, can also be regarded as a measurement of platelet aggregation. Still, the inner-link between $MA_{\text{Thrombin}}$ and PVIs in CAD patients remains confusing. Otherwise, inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (Fbg), have been confirmed to be associated with the occurrence and poor prognosis of ACS tightly [12–14]. But whether there exists any
relationship between MA_{thrombin} and inflammatory markers is controversial either.

The aim of this study was to detect the magnitude of MA_{thrombin} and its relationship with PVIs and inflammatory markers in patients with different clinical types of CAD.

RESULTS

Patient demographics

Baseline characteristics of all the participants are illustrated in Table 1, according to different clinical type of CAD. There was no statistical difference about age, sex, tobacco use, body mass index (BMI), history of diabetes, dyslipidemia, and stroke in each group, but the prevalence of hypertension varied (P=0.024). Both aspirin and anti-coagulation application were significantly different in each group (P<0.001), however, prescriptions of statins, β-blockers, and proton pump inhibitors (PPIs) were demonstrated equally between groups. Moreover, patients with myocardial infarction tended to present higher white blood cell count (WBC), fasting blood glucose, and N-terminal pro-brain natriuretic peptide (NT-proBNP), as well as lower left ventricular ejection fraction (LVEF).

Correlation of TEG measured MA_{thrombin} and CAD types

As displayed in Table 2, there were significantly statistical differences in the magnitudes of MA_{thrombin} among groups (P=0.026). Moreover, MA_{thrombin} appeared to be higher in patients with AMI (including ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI)) than those with angina pectoris (including unstable angina pectoris (UAP) and stable angina pectoris (SAP)) (64.51±3.32 vs 62.32±3.79, P<0.001). However, no significant difference about MPV, PDW, and P-LCR could be found in each group. In addition, inflammatory markers, including hs-CRP and Fbg, also elevated in STEMI and SAP patients. In addition, MA_{thrombin} was more likely to have statistical correlation with hs-CRP tightly correlated to PVIs in patients with NSTEMI, but was much higher in STEMI and NSTEMI groups (P<0.001, P=0.007).

Correlation of MA_{thrombin} and PVIs

Table 3 illustrates the relationship between MA_{thrombin} and PVIs. Although we tried to analyze the association between MA_{thrombin} and PVIs in each group, statistical correlation of these two kinds of biomarkers could only be found in NSTEMI patients. Since their link might interact with different confounders, three consecutive models of multivariate adjustment were created. The first model adjusted for age and sex, the second included lifestyle and chronic disease variables (smoking, BMI, diabetes, hypertension, dyslipidemia, stroke, WBC, platelet count, fasting blood glucose, and serum creatinine). Finally, we performed the third model taking medication history (aspirin, anti-coagulant medications, statins, β-blockers, and PPIs) into consideration. As shown in Table 3, MA_{thrombin} and PVIs were still correlated in NSTEMI group after full adjustment by multiple linear regression analysis (MPV, r=0.393, P=0.007; PDW, r=0.334, P=0.023; P-LCR, r=0.382, P=0.008).

Correlation of MA_{thrombin} and inflammatory markers

Table 3 also illustrates the relationship between MA_{thrombin} and hs-CRP. When multivariate analysis in subgroups were conducted, the correlation between the two biomarkers could be detected in STEMI and SAP patients upon full adjustment (STEMI, r=0.499, P<0.001; SAP, r=0.444, P=0.001). Meanwhile, MA_{thrombin} also existed a positive correlation with Fbg in each group, independent of the CAD type (Table 3). Additionally, we analyzed the relationship between hs-CRP and Fbg and found that they were also correlated in all groups (P<0.001).

DISCUSSION

To our knowledge, this is the first observational study to explore the potential relationship between magnitude of MA_{thrombin} measured by TEG and PVIs along with inflammatory markers in different types of Chinese CAD patients. After adjusting for potential confounders (including age, sex, smoking, BMI, diabetes, hypertension, dyslipidemia, stroke, WBC, platelet count, fasting blood glucose, serum creatinine, aspirin, current use of anti-coagulant medications, statins, β-blockers, and PPIs), we found there was a trend that MA_{thrombin} was tightly correlated to PVIs in patients with NSTEMI, but was more likely to have statistical correlation with hs-CRP in STEMI and SAP patients. In addition, MA_{thrombin} was correlated to Fbg in all the patients enrolled.

Previous studies suggest that platelet not only participates in coronary thrombosis, but also contributes to atherosclerosis and endothelial injury by secreting mediators during the development of CAD [15, 16]. Some biomarkers of platelet activation may relate to the presentation of CAD clinically [5, 16, 17]. Up till now, MA_{thrombin} measured by TEG has been shown to reflect the maximal potential aggregability of platelet, which, to some extent, can evaluate the contribution from platelet to coronary thrombosis specifically [5, 13, 18, 19]. Moreover, MA_{thrombin} has been suggested as a predictor of adverse cardiac events after coronary stent implantation [13, 20, 21]. In this study, we revealed that the magnitude of MA_{thrombin} was much higher in STEMI and NSTEMI patients than that in UAP and SAP patients, which partly supported the previous hypotheses and provided further evidence to the diagnostic and evaluating value of platelet aggregation assay in CAD patients.

Although many factors may confound the measurement of PVIs, several investigations have still demonstrated PVIs, such as MPV, PDW, and P-LCR, to...
be elevating in ACS and have hypothesized MPV to be an effective indicator of platelet activation in vivo [9–11, 22]. Our research didn’t find statistical difference of PVIs among each group, which seemed to be controversial with previous studies [9–11, 22]. Inflammation plays a vital role in the formation, development, and disruption of atherosclerotic plaques, therefore, coronary atherosclerosis (AS) can also be regarded as an inflammatory process [4]. As a marker for inflammation, hs-CRP reflects a wide range of inflammatory conditions, which has been proved to be tightly associated with the occurrence and poor prognosis of CAD [12–14]. Fbg, as a coagulation factor, has also been recognized as an inflammatory marker as well. Our research showed serum hs-CRP and Fbg levels were higher in AMI patients than angina cases, in accordance with those earlier findings.

Table 1: Demographics of study population according to clinical presentation

|                | Overall | STEMI  | NSTEMI | UAP     | SAP     | P-value |
|----------------|---------|--------|--------|---------|---------|---------|
|                | N=206   | N=67   | N=50   | N=33    | N=56    |         |
| Baseline characteristic |         |        |        |         |         |         |
| Age           | 62.99±11.01 | 64.60±11.53 | 62.98±12.05 | 63.70±8.57 | 60.66±10.56 | 0.255   |
| Male(N,%)     | 156(75.7) | 51(76.1) | 39(78.0) | 24(72.7) | 42(75.0) | 0.955   |
| Smoking(N,%)  | 110(53.4) | 41(61.2) | 28(56.0) | 18(54.5) | 23(41.1) | 0.157   |
| BMI(kg/m²)    | 24.89±1.48 | 24.67±1.29 | 24.89±1.51 | 24.89±1.73 | 25.16±1.52 | 0.338   |
| Hypertension(N,%) | 130(63.1) | 34(50.7) | 39(78.0) | 20(60.6) | 37(66.1) | 0.024   |
| Diabetes mellitus(N,%) | 72(35.0) | 28(41.8) | 19(38.0) | 12(36.4) | 13(23.2) | 0.171   |
| Dyslipidemia(N,%) | 43(20.9) | 12(17.9) | 15(30.0) | 6(18.2) | 10(17.9) | 0.343   |
| Stroke(N,%)   | 16(7.8)  | 5(7.5)  | 4(8.0)  | 2(6.1)  | 5(8.9)  | 0.969   |
| Medication history |         |        |        |         |         |         |
| Aspirin(N,%)  | 57(44.2) | 10(18.2) | 15(39.5) | 13(81.2) | 19(95.0) | <0.001  |
| Anti-coagulation(N,%) | 143(69.4) | 66(98.5) | 47(94.0) | 19(57.6) | 11(19.6) | <0.001  |
| Statins(N,%)  | 204(99.0) | 67(100.0) | 50(100.0) | 32(97.0) | 55(98.2) | 0.393   |
| β-blockers(N,%) | 189(91.7) | 61(91.0) | 45(90.0) | 31(93.9) | 52(92.9) | 0.909   |
| PPI(N,%)      | 57(27.7) | 30(44.8) | 21(42.0) | 1(3.0)  | 5(8.9)  | <0.001  |
| Other characteristics |         |        |        |         |         |         |
| WBC(×10^9/L)  | 7.52±2.76 | 9.44±3.48 | 7.48±1.80 | 6.24±1.56 | 6.03±1.34 | <0.001  |
| Platelet(×10^9/L) | 198.07±53.09 | 206.15±60.67 | 197.82±48.22 | 182.12±44.00 | 198.04±51.56 | 0.210   |
| Fasting blood glucose(mmol/L) | 6.32±2.35 | 7.41±2.88 | 6.34±2.06 | 5.89±2.30 | 5.25±0.98 | <0.001  |
| Serum creatinine(mmol/L) | 76.21±20.66 | 75.23±21.89 | 75.24±16.96 | 82.03±29.35 | 74.82±15.37 | 0.374   |
| NT-proBNP/ng/L | 931.13±1459.31 | 1449.45±1608.49 | 1250.59±1903.66 | 610.68±710.20 | 216.82±551.75 | <0.001  |
| Lp(a)(mg/L)   | 209.30±201.45 | 165.03±149.96 | 240.45±210.04 | 246.94±276.08 | 213.95±193.31 | 0.136   |
| LVEF(%)       | 62.08±9.22  | 57.17±9.43  | 63.68±7.62  | 61.31±9.43  | 66.94±7.02  | <0.001  |

Data are expressed as mean ± standard deviation(SD) or number of patients (percentage).

STEMI, ST segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; UAP, unstable angina pectoris; SAP, stable angina pectoris; BMI, body mass index; PPI, proton pump inhibitor; WBC, white blood cell; NT-proBNP, N-terminal pro-brain natriuretic peptide; Lp(a), Lipoprotein(a); LVEF, left ventricular ejection fraction.
From the view of biomarkers, our study demonstrated that MA\textsubscript{Thrombin}, as a parameter of platelet aggregation, elevated in AMI patients, correlating to PVIs in NSTEMI group, but linking with inflammatory markers in STEMI group. These findings may provide new clinical evidences to the pathogenesis of platelet aggregation in AMI. Several probable mechanisms might have been proposed but the exact biologic mechanisms are not fully understood. NSTEMI is more likely to be caused by severe coronary lesions and repeated plague ruptures, which could induce platelet activation and may enhance platelet aggregating function in a relative long term. Cellular structure can determine but also can be influenced by function. Since larger platelets can contain and release more pro-aggregating mediators [9–11], PVIs might higher up to match this functional enhancement during the development of NSTEMI. In contrast, when STEMI occurs, coronary plaque rupture leads to platelet aggregating immediately, which contributes to the formation of coronary thrombus. Platelets adhere to vessels and release mediators that increase endothelial cell activation and leukocyte recruitment [8, 14, 15], as a result, expression of hs-CRP and Fbg are up-regulated rapidly. In the meantime, Fbg is an important factor of clotting system, it can play a key role in the blood clotting cascade. However, there is not enough time allowing PVIs to higher up during the acute phase. From another perspective, the development of atherosclerotic plaque can be regarded as a chronic inflammatory process. Plaque rupture may exacerbate the chronic inflammation acutely. We failed to find the association between MA\textsubscript{Thrombin} and inflammatory markers in patients with NSTEMI or between MA\textsubscript{Thrombin} and PVIs in patients with STEMI, which might also due to the probable machnisms mentioned above. In brief, NSTEMI is more likely to be a result of severe coronary stenosis in a relative long term rather than plaque rupture alone, so that, the correlation between MA\textsubscript{Thrombin} and markers of acute phase reaction couldn’t be detected sharply; however, STEMI are to the opposite.

As a cross-sectional study, our research might be affected by reverse causality and survivor bias. Several limitations should be acknowledged. First, this was a retrospective study and the study groups were of different sample sizes, moreover, baseline characteristics in each group were imbalanced. Second, although we have confirmed MA\textsubscript{Thrombin} to be concerned with PVIs in NSTEMI and with inflammatory markers in STEMI, a prospective case-control study should be conducted to confirm these findings. Third, to clarify the exactly biologic mechanisms, further experimental investigations are needed. Moreover, the usage of clopidogrel or ticagrelor were not taken into baseline characteristics collection, which might skew the results potentially. Finally, other possibility of residual confounders related to these issues remains.

In conclusion, our data shows that both MA\textsubscript{Thrombin} and inflammatory markers elevate in patients with AMI. Interestingly, MA\textsubscript{Thrombin} is correlated to PVIs in NSTEMI but has inner-link with inflammatory markers in STEMI.

| Characteristics | Overall | STEMI | NSTEMI | UAP | SAP | P-value |
|-----------------|---------|-------|--------|-----|-----|---------|
|                 | N=206   | N=67  | N=50   | N=33 | N=56 |         |
| Thrombelastography |         |       |        |     |     |         |
| MA\textsubscript{Thrombin} (mm) | 63.57±5.29 | 64.23±5.71 | 64.90±4.47 | 62.24±5.81 | 62.37±4.81 | 0.026   |
| Platelet volume indices |         |       |        |     |     |         |
| MPV(fL)         | 11.14±1.05 | 11.09±0.95 | 11.14±1.03 | 11.30±1.06 | 11.10±1.18 | 0.794   |
| PDW(%)          | 13.60±2.29 | 13.44±2.04 | 13.70±2.27 | 13.96±2.38 | 13.49±2.57 | 0.706   |
| P-LCR(%)        | 34.08±8.26 | 33.96±7.60 | 34.16±8.30 | 35.56±8.83 | 33.30±8.73 | 0.665   |
| Inflammatory markers |         |       |        |     |     |         |
| hs-CRP(mg/L)    | 10.68±19.34 | 13.46±19.22 | 18.94±28.04 | 5.60±11.57 | 3.00±5.03 | <0.001  |
| Fbg(mg/mL)      | 306.42±95.19 | 318.12±102.88 | 331.42±98.78 | 303.09±93.11 | 272.05±73.44 | 0.007   |

Data are expressed as mean ± standard deviation(SD).

STEMI, ST segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; UAP, unstable angina pectoris; SAP, stable angina pectoris; MPV, mean platelet volume; PDW, platelet distribution width; P-LCR, platelet-large cell ratio; hs-CRP, high-sensitivity C-reactive protein; Fbg, Fibrinogen.
Table 3: Association between $\text{MA}_{\text{Thrombin}}$ and platelet volume indices or inflammatory markers according to clinical presentation

|                     | Overall (N=206) | STEMI (N=67) | NSTEMI (N=50) | UAP (N=33) | SAP (N=56) |
|---------------------|----------------|--------------|--------------|------------|------------|
|                     | Standardized correlation coefficient | P-value | Standardized correlation coefficient | P-value | Standardized correlation coefficient | P-value | Standardized correlation coefficient | P-value | Standardized correlation coefficient | P-value |
| **Platelet volume indices** | | | | | | | | |
| MPV                 |                | | | | | | | |
| Model 1             | 0.038          | 0.567        | -0.034       | 0.775      | 0.228       | 0.094      | 0.240          | 0.184      | -0.073          | 0.560      |
| Model 2             | 0.218          | **0.001**    | 0.108        | 0.408      | **0.388**   | **0.002**  | 0.246          | 0.127      | 0.210          | 0.084      |
| Model 3             | **0.231**      | `<0.001`     | 0.093        | 0.505      | **0.393**   | **0.007**  | 0.291          | 0.136      | 0.164          | 0.195      |
| PDW                 |                | | | | | | | |
| Model 1             | 0.042          | 0.533        | 0.007        | 0.955      | 0.145       | 0.287      | 0.209          | 0.247      | -0.058          | 0.643      |
| Model 2             | 0.229          | **0.001**    | 0.136        | 0.309      | **0.344**   | **0.009**  | 0.221          | 0.182      | **0.271**       | **0.031**  |
| Model 3             | **0.247**      | `<0.001`     | 0.125        | 0.380      | **0.334**   | **0.023**  | 0.298          | 0.151      | 0.221          | 0.091      |
| P-LCR               |                | | | | | | | |
| Model 1             | 0.073          | 0.276        | 0.022        | 0.855      | 0.227       | 0.096      | 0.265          | 0.141      | -0.064          | 0.615      |
| Model 2             | **0.252**      | `<0.001`     | 0.143        | 0.275      | **0.376**   | **0.003**  | 0.268          | 0.097      | **0.282**       | **0.027**  |
| Model 3             | **0.260**      | `<0.001`     | 0.137        | 0.325      | **0.382**   | **0.008**  | 0.309          | 0.110      | 0.232          | 0.080      |
| **Inflammatory markers** | | | | | | | | |
| hs-CRP              |                | | | | | | | |
| Model 1             | **0.274**      | `<0.001`     | **0.476**    | `<0.001`   | 0.022       | 0.873      | 0.208          | 0.253      | 0.201          | 0.116      |
| Model 2             | **0.266**      | `<0.001`     | **0.485**    | `<0.001`   | -0.144      | 0.227      | 0.141          | 0.450      | 0.213          | 0.119      |
| Model 3             | **0.228**      | `<0.001`     | **0.499**    | `<0.001`   | -0.166      | 0.210      | -0.005         | 0.983      | **0.444**       | **0.001**  |
| Fbg                 |                | | | | | | | |
| Model 1             | **0.507**      | `<0.001`     | **0.520**    | `<0.001`   | **0.449**   | **0.001**  | **0.552**      | **0.001**  | **0.622**       | **0.000**  |
| Model 2             | **0.439**      | `<0.001`     | **0.482**    | `<0.001`   | **0.331**   | **0.017**  | **0.368**      | **0.040**  | **0.647**       | `<0.001`  |
| Model 3             | **0.417**      | `<0.001`     | **0.500**    | `<0.001`   | **0.312**   | **0.042**  | 0.278          | 0.182      | **0.477**       | `<0.001`  |

Values are expressed as standardized coefficients and P-value.

STEMI, ST segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; UAP, unstable angina pectoris; SAP, stable angina pectoris; MPV, mean platelet volume; PDW, platelet distribution width; P-LCR, platelet-large cell ratio; hs-CRP, high-sensitivity C-reactive protein; Fbg, fibrinogen.

Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, smoking, BMI, diabetes, hypertension, dyslipidemia, stroke, white blood cell count, platelet count, fasting blood glucose, and serum creatinine.
Model 3: adjusted for age, sex, smoking, BMI, diabetes, hypertension, dyslipidemia, stroke, white blood cell count, platelet count, fasting blood glucose, serum creatinine, aspirin application, current use of anti-coagulant medications, statins, β-blockers, and PPIs.

patients, which may suggest different mechanisms of platelet aggregation in these two types of AMI. Since $\text{MA}_{\text{Thrombin}}$ not only can reflect the functional status of platelet, but also can reflect inflammation status indirectly, this marker may be used as a potential clinical parameter to evaluate platelet aggregation and inflammation together. Further investigations are necessary to confirm these findings.

**MATERIALS AND METHODS**

**Study design and patients**

From January to September 2015, 206 Chinese CAD patients admitted to Zhongshan Hospital, Fudan University were enrolled in this observational single centre study. Exclusion criteria were: older than 75 years of age,
with a history of pulmonary artery embolism, deep venous thrombosis, peripheral arterial disease, anemia, malignant disease, severe renal or hepatic insufficiency, total platelet count $\leq 100 \times 10^9$/L, increased risk of bleeding or hematologic disorder, accepted thrombolytic therapy, usage of warfarin or new oral anticoagulant (NOAC), and missing data. The patients were grouped according to their clinical presentation [23, 24]. Finally, sixty-seven ST segment elevation myocardial infarction (STEMI) patients, fifty non-ST segment elevation myocardial infarction (NSTEMI) patients, thirty-three unstable angina pectoris (UAP) patients and fifty-six stable angina pectoris (SAP) patients were taken into consideration. All the subjects enrolled had been under dual anti-platelet therapy before they received coronary angiogram, which included aspirin 100 mg per day and clopidogrel 75 mg per day after each loading dose of 300 mg. The study protocol was approved by the hospital's medical ethics committee, and informed consent was obtained from each patient.

**Blood samples**

Blood samples were drawn by trained phlebotomists from the subjects before they received coronary angiogram. A complete blood cell count, including MPV, PDW, and PLC-R, was obtained by Sysmex XE-2100. Blood biochemical analysis including hs-CRP was tested by Hitachi 7600 auto-biochemistry analyzer (Tokyo, Japan), while plasma level of Fbg was measured by Sysmex CA-1500 type automatic programming coagulation analyzer.

**Thromboelastography**

TEG of citrated whole blood was performed using according to the manufacturer’s instruction (Haemonetics, New York, USA). One mL whole blood was added into standard container coated with Kaolin (activator) and inverted five times. After 5 minutes resting, 340μL mixtures were loaded in a TEG cup containing 20μl of CaCl₂, TEG was performed immediately and lasted from 15 minutes to 2 hours (depending on the blood samples) until MA$_{thrombin}$ readout was recorded. If patients were under anti-coagulation therapies by intravenous heparin or low molecular weight heparin during sample collection, heparinase coated TEG cups were used to generate TEG profiles.

**Assessment of demographic variables and other risk factors**

Information on demographic and clinical characteristics (e.g., age, sex, smoking, and history of diseases and medication) were collected. Smoking was classified according to “current smoker or quitting less than one year”, or “nonsmoker or quitting more than one year”. BMIs were defined based on measured heights (accurate to 0.1 cm) and weights (accurate to 0.1 kg), and calculated as the body weight (kg) divided by the square of height (m$^2$). The information of disease history included hypertension, diabetes, dyslipidemia, and stroke. Hypertension was based on a history of hypertension, or use of antihypertensive medication, or a systolic pressure $\geq 140$ mmHg, or a diastolic blood pressure $\geq 90$ mmHg. Diabetes was defined according to a self-reported history, current use of insulin or oral hypoglycemic agents, or fasting blood glucose level $\geq 7.0$ mmol/L. Dyslipidemia was diagnosed on the basis of a self-reported history, blood total cholesterol (TC) $\geq 5.18$ mmol/L or triglycerides (TG) $\geq 1.7$ mmol/L or low-density lipoprotein cholesterol (LDL-c) $\geq 3.77$ mmol/L or high-density lipoprotein cholesterol (HDL-c)$<1.04$ mmol/L or current use of antilipemic agents. Medication history, including aspirin, current use of anti-coagulant medications (including intravenous heparin and low molecular weight heparin), statins, β-blockers, and PPIs were documented as “yes” or “no”. Levels of serum creatinine, fasting blood glucose, and other biomarkers were detected along with PVIs and inflammatory markers as mentioned above. Left ventricular ejection fraction (LVEF) were measured by ultrasonic cardiogram.

**Statistical analysis**

Statistical analyses were performed using SPSS software, version 20.0 (SPSS Inc., Chicago, Illinois). Continuous variables were described by mean ± standard deviation (SD) and were analyzed using ANOVA analysis. Categorical variables were described by percentages and were compared using Chi-square tests. Multiple linear regression was used to determine the correlation among continuous variable in order to assess the association between MA$_{thrombin}$ and levels of PVIs and inflammatory markers with other parameters such as age, sex, hypertension, diabetes and BMI adjusted. All statistical tests were 2-sided, and $P<0.05$ was accepted as statistically significant.

**ACKNOWLEDGMENTS**

This study was mainly proposed by H-CL, H-YW and J-BG. H-CL and J-SY analyzed data. H-CL and H-YW wrote the draft. All authors read, reviewed and approved the final manuscript. J-BG had primary responsibility for final content.

**CONFLICTS OF INTEREST**

The authors declare no competing financial interests.

**GRANT SUPPORT**

Our work was supported by National Natural Science Foundation of China [81300152] and Doctoral Starting up Foundation of Liaoning Province [201601234].
REFERENCES

1. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990; 322:1549-1554.

2. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010; 116:2627-2634.

3. Priebe HJ. Perioperative myocardial infarction—aetiology and prevention. Br J Anaesth. 2005; 95:3-19.

4. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32:2045-2051.

5. Wu H, Qian J, Wang Q, Lv H, Sun A, Ge J. Thrombin induced platelet-fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction. Int J Cardiol. 2014; 172:e24-e25.

6. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten BJ, Kirtane A, Siller-Matula J, Mahla E, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62:2261-2273.

7. Jeong YH, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost. 2014; 111:713-724.

8. Lu D, Owens J, Kreutz RP. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. Thromb Res. 2013; 132:e94-e98.

9. Tsiara S, Eliafs M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003; 9:177-190.

10. Damodor S, Ganesh KV, Murthy S. Mean platelet volume does not predict risk of myocardial infarction or coronary artery disease in Indian patients. Platelets. 2008; 19:80-81.

11. Assiri AS, Jamil AM, Mahfouz AA, Mahmoud ZS, Ghallab M. Diagnostic importance of platelet parameters in patients with acute coronary syndrome admitted to a tertiary care hospital in southwest region, Saudi Arabia. J Saudi Heart Assoc. 2012; 24:17-21.

12. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999; 34:1512-1521.

13. Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010; 160:346-354.

14. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54:2129-2138.

15. Lindemann S, Kramer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007; 5:203-211.

16. Langer HF, Bigalke B, Seizer P, Stellos K, Fateh-Moghadam S, Gawaz M. Interaction of platelets and inflammatory endothelium in the development and progression of coronary artery disease. Semin Thromb Hemost. 2010; 36:131-138.

17. Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics. 2012; 22:887-890.

18. Bowbrick VA, Mikhailidis DP, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost. 2003; 9:137-142.

19. Bailey LA, Sistino JJ, Uber WE. Is platelet function as measured by thrombelastograph monitoring in whole blood affected by platelet inhibitors? J Extra Corpor Technol. 2005; 37:43-47.

20. Gurbel PA, Bliden KP, Gayer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STEMTING Study. J Am Coll Cardiol. 2005; 46:1820-1826.

21. Gurbel PA, Bliden KP, Cohen E, Navickas IA, Singla A, Antonino MJ, Fissha M, Kreutz RP, Bassi AK, Tantry US. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis. 2008; 19:268-275.

22. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010; 8:148-156.

23. Lindemann S, Kramer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007; 5:203-211.

24. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54:2129-2138.

25. Thyegezen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thyegezen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012; 60:1581-1598.

26. Amsterdam EA, Wenger NK, Brindis RG, Casey DJ, Ganiats TG, Holmes DJ, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-e426.